MECHANISMS OF SIGNAL TRANSDUCTION
A Conserved Calcineurin-binding Motif in Human T Lymphotropic Virus Type 1 p12I Functions to Modulate Nuclear Factor of Activated T Cell Activation*

https://doi.org/10.1074/jbc.M210210200Get rights and content
Under a Creative Commons license
open access

The PXIXIT calcineurin binding motif or highly related sequences are found in a variety of calcineurin-binding proteins in yeast, mammalian cells, and viruses. The accessory protein p12I encoded in the HTLV-1 pX ORF I promotes T cell activation during the early stages of HTLV-1 infection by activating nuclear factor of activated T cells (NFAT) through calcium release from the endoplasmic reticulum. We identified in p12I, a conserved motif, which is highly homologous with the PXIXIT calcineurin-binding motif of NFAT. Both immunoprecipitation and calmodulin agarose bead pull-down assays indicated that wild type p12I and mutants of p12I that contained the motif-bound calcineurin. In addition, an alanine substitution p12I mutant (p12I AXAXAA) had greatly reduced binding affinity for calcineurin. We then tested whether p12I binding to calcineurin affected NFAT activity. p12I competed with NFAT for calcineurin binding in calmodulin bead pull-down experiments. Furthermore, the p12I AXAXAA mutant enhanced NFAT nuclear translocation compared with wild type p12I and increased NFAT transcriptional activity 2-fold greater than wild type p12I. Similar to NFAT, endogenous calcineurin phosphatase activity was increased in Jurkat T cells expressing p12Iindependent of its calcineurin binding property. Thus, the reduced binding of p12I to calcineurin allows enhanced nuclear translocation and transcription mediated by NFAT. Herein, we are the first to identify a retroviral protein that binds calcineurin. Our data suggest that HTLV-1 p12I modulates NFAT activation to promote early virus infection of T lymphocytes, providing a novel mechanism for retrovirus-mediated cell activation.

Cited by (0)

Published, JBC Papers in Press, February 24, 2003, DOI 10.1074/jbc.M210210200

*

This work was supported by National Institutes of Health Grants RR-14324, AI-01474, and CA-92009 (to M. D. L.) and NCI, National Institutes of Health, Grant CA-70529 (to the Ohio State University Comprehensive Cancer Center).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

Present address: Howard Hughes Medical Institute, Molecular Pathogenesis Program, The Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY 10016.